Vertex Pharmaceuticals 株価情報 (NASDAQ: VRTX)

最新ニュース Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Analyst Ratings

VRTX

Vertex Pharmaceuticals（NASDAQ:VRTX）に14人のアナリストが過去3か月間で分析を行ったところ、その視点は強気から弱気まで多様なものとなった。

14人のアナリスト分析からVertexの市場動向を追う

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

25 analysts have shared their evaluations of Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $479.6, a high estimate of $550.00, and a low estimate of $407.00. This current average represents a 1.63% decrease from the previous average price target of $487.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1740085227_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Vertex Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$520.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$407.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$450.00</td>
<td>$433.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$467.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$459.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$433.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$460.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$533.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$460.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>$426.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$418.00</td>
<td>$509.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$520.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$535.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$522.00</td>
<td>$545.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$494.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vertex Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Discovering Vertex Pharmaceuticals: A Closer Look</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Vertex Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 15.66%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 31.35%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.7%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 4.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Vertex Pharmaceuticals's Future

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $407 to $408.

News

Price Target

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $408

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst C. Gregory Peters upgraded the rating for Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) from Outperform to Strong Buy and raised the price target from $70 to $80. Mercury General shares closed at $50.09 on Tuesday. <a href="https://www.benzinga.com/quote/MCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Reginald Smith upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Underweight to Neutral and boosted the price target from $57 to $79. Upstart shares closed at $67.34 on Tuesday. <a href="https://www.benzinga.com/quote/upst/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Joseph Moore upgraded the rating for NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) from Equal-Weight to Overweight and increased the price target from $231 to $257. NXP Semiconductors shares closed at $210.97 on Tuesday. <a href="https://www.benzinga.com/quote/nxpi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Quinn Bolton upgraded GLOBALFOUNDRIES Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) from Hold to Buy and announced a $50 price target. Maplebear shares closed at $40.10 on Tuesday. <a href="https://www.benzinga.com/quote/gfs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Whitney Ijem upgraded the rating for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Sell to Hold and raised the price target from $408 to $424. Vertex Pharmaceuticals shares closed at $455.22 on Tuesday. <a href="https://www.benzinga.com/quote/vrtx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="405" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-1024x405.png" alt="" class="wp-image-778775" style="width:473px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-1024x405.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-300x119.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-768x303.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105.png 1182w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

NXPI

UPST

This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Canaccord Genuity analyst Whitney Ijem upgrades Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Sell to Hold and raises the price target from $408 to $424.

Canaccord Genuity Upgrades Vertex Pharmaceuticals to Hold, Raises Price Target to $424

Truist Securities analyst Joon Lee maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and raises the price target from $460 to $520.

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $520

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $402 to $407.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $407

Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported mixed results for its fourth <a href="https://www.benzinga.com/quote/VRTX/earnings">quarter on Monday</a>.
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per share. The company reported quarterly sales of $2.912 billion which beat the analyst consensus estimate of $2.781 billion.
&#8220;2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base, disease areas of focus, R&amp;D pipeline, and geographies to continue to deliver long-term value to both patients and shareholders,&#8221; said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
Vertex Pharmaceuticals said it sees FY25 revenue of $11.75 billion to $12.00 billion, versus market estimates of $11.84 billion.
Vertex Pharmaceuticals shares fell 2.5% to trade at $458.15 on Tuesday.
These analysts made changes to their price targets on Vertex Pharmaceuticals following earnings announcement.
<ul>
<li>Morgan Stanley analyst Matthew Harrison maintained Vertex Pharmaceuticals with an Equal-Weight and raised the price target from $450 to $459.</li>
<li>Barclays analyst Gena Wang maintained the stock with an Equal-Weight and raised the price target from $435 to $46.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein, meanwhile, reiterated Vertex Pharmaceuticals with a Buy and maintained a $550 price target.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="625" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11095438/image-97-1024x625.png" alt="" class="wp-image-776741" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11095438/image-97-1024x625.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11095438/image-97-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11095438/image-97-768x468.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11095438/image-97.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

Earnings

Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $433 to $450.

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $450

Cantor Fitzgerald analyst Olivia Brayer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and maintains $480 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $480 Price Target

Barclays analyst Gena Wang maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $435 to $467.

Barclays Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $467

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and maintains $550 price target.

HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $550 Price Target

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $450 to $459.

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $459

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Management

Vertex COO Stuart Arbuckle To Retire Jul. 2025

Guidance

Vertex Pharmaceuticals Sees FY25 Revenue $11.75B-$12.00B vs. $11.84B Est.

Earnings Beats

Earnings Misses

Vertex Pharmaceuticals Q4 2024 Adj. EPS $3.98 Misses $4.03 Estimate

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported quarterly earnings of $3.50 per share which missed the analyst consensus estimate of $3.57 by 1.96 percent. The company reported quarterly sales of $2.912 billion which beat the analyst consensus estimate of $2.781 billion by 4.70 percent. This is a 15.66 percent increase over sales of $2.518 billion the same period last year.

Vertex Pharmaceuticals Q4 2024 GAAP EPS $3.50 Misses $3.57 Estimate, Sales $2.912B Beat $2.781B Estimate

CDNA

NTRA

Live On CNBC, Amy Raskin Announces Trimmed Vertex Pharmaceuticals ; Trimmed Kadant Position; Trimmed Natera Position; Bought CareDx

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is set to report <a href="https://www.benzinga.com/quote/VRTX/earnings">fourth quarter earnings</a> after the market closes Monday. Biotech investors are bracing for impact.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10085744/Screenshot-2025-02-10-at-7.27.22-PM.png" alt="" class="wp-image-774596" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10085744/Screenshot-2025-02-10-at-7.27.22-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10085744/Screenshot-2025-02-10-at-7.27.22-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The stock has climbed 15.66% year-to-date, recovering from last year's volatility. With selling pressure creeping in, the question is whether this rally has legs, or if it&#8217;s time for a reset.
<h2 class="wp-block-heading">Wall Street's Expectations: Solid Numbers Or A Reality Check?</h2>
Wall Street expects Vertex to post EPS of $4.03 on revenue of $2.78 billion, per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">Benzinga Pro</a> data. 
But beyond the numbers, the real focus is on the company's upcoming drug launches and how they could fuel future growth.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526731/unitedhealth-vertex-pharmaceuticals-axon-enterprise-and-a-major-energy-stock-cnbcs-final-trades">UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC&#8217;s &#8216;Final Trades&#8217;</a>
<h2 class="wp-block-heading">Pipeline Watch: Can Alyftrek And Suzetrigine Deliver?</h2>
JPMorgan analyst Jessica Fye sees 2025 as a make-or-break year for Vertex.
The company is rolling out Alyftrek, its latest cystic fibrosis (CF) treatment and preparing for a potential suzetrigine launch in acute pain. Investors will be watching management's commentary on these new products closely, especially after suzetrigine's mixed Phase II results in LSR (large sensory neuropathy).
Fye expects a solid launch for Alyftrek, modeling $376 million in 2025 revenue though but suzetrigine's adoption remains uncertain, with pricing a key factor.
<h2 class="wp-block-heading">VRTX Stock Technicals: Bullish, But With Risks</h2>
Technicals are giving mixed signals. VRTX stock is trading at $469.32, above its eight-day, 20-day, 50-day and 200-day moving averages, flashing buy signals across the board.
The MACD (moving average convergence/divergence) indicator is bullish. RSI (relative strength index) at 62.06 suggests there&#8217;s still room to run.
But selling pressure is creeping in, hinting at potential turbulence ahead.
<h2 class="wp-block-heading">Can Vertex Stock Keep Its Momentum?</h2>
Vertex needs to deliver more than just a solid quarter though investors want confidence in its 2025 pipeline. Any slip-up in guidance could shake the stock's recent momentum. Stay tuned.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43589292/top-wall-street-forecasters-revamp-vertex-pharmaceuticals-price-expectations-ahead-of-q4-earnings">Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Technicals

Previews

Tech

General

Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?

Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/vrtx/earnings">closing bell, on Monday, Feb. 10, 2025.</a>
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly revenue of $2.78 billion, compared to $2.52 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 30, Vertex Pharmaceuticals announced it secured FDA approval for JOURNAVX. Also, the company announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access CASGEVY.
Vertex Pharmaceuticals shares fell 2.5% to close at $469.32 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Rating</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating and raised the price target from $535 to $550 on Jan. 31, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight with a price target of $460 on Jan. 30, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst Joon Lee maintained a Buy rating and lowered the price target from $550 to $460 on Dec. 23, 2024. This analyst has an accuracy rate of 76%.</li>
<li>JP Morgan analyst Jessica Fye maintained an Overweight rating and cut the price target from $503 to $500 on Dec. 23, 2024. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst Even Seigerman maintained an Outperform rating and cut the price target from $566 to $520 on Dec. 20, 2024. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-1024x626.png" alt="" class="wp-image-774084" style="width:543px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-1024x626.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings

Press Releases

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Economics

Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

AM Best Assigns Credit Ratings to Torreyana Insurance Company, Inc.

Vertex to Participate in Upcoming March Investor Conferences

IMGN

ZLAB

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

RBC Capital

Canaccord Genuity

Truist Securities

Scotiabank

Cantor Fitzgerald

Vertex Pharm

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Vertex Pharmaceuticals（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>）に14人のアナリストが過去3か月間で分析を行ったところ、その視点は強気から弱気まで多様なものとなった。
以下の表は、アナリストによる最近のレーティングの簡潔な概要を提供し、過去30日間の株価動向に関する見解を示し、総合的な視点から先月と今月の比較を行っている。
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th style="text-align: right;">強気</th>
<th style="text-align: right;">やや強気</th>
<th style="text-align: right;">無関心</th>
<th style="text-align: right;">やや弱気</th>
<th style="text-align: right;">弱気</th>
</tr>
</thead>
<tbody>
<tr>
<td>総合格付け数</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>最近30日</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1か月前</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2か月前</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3か月前</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
アナリストによる評価のポイント
アナリストによって評価された12か月後の株価ターゲットは、平均474.86ドル、最高評価555.00ドル、最低評価376.00ドルとなり、アナリストたちの現在の総合見解を示す6.67％増の平均となった。
<img decoding="async" src="https://www.benzinga.com/files/images/story/2024/1722434476_0.png" alt="price target chart" />
<h2>アナリストの評価を調査：詳細な調査</h2>
最近のアナリストの行動の詳細な分析は、財務専門家がVertex Pharmaceuticalsをどのように認識しているかを明らかにする。以下のサマリーは、主要アナリスト、彼らの最近の評価、格付けおよび株価ターゲットの調整の概要を示している。
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>アナリスト</th>
<th>アナリスト会社</th>
<th>行動</th>
<th>評価</th>
<th>現在の株価ターゲット</th>
<th>以前の株価ターゲット</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>引き上げ</td>
<td>Sell</td>
<td>376.00ドル</td>
<td>371.00ドル</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>引き上げ</td>
<td>Buy</td>
<td>500.00ドル</td>
<td>450.00ドル</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>引き上げ</td>
<td>Overweight</td>
<td>480.00ドル</td>
<td>440.00ドル</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>引き上げ</td>
<td>Buy</td>
<td>500.00ドル</td>
<td>462.00ドル</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>引き上げ</td>
<td>Equal-Weight</td>
<td>455.00ドル</td>
<td>402.00ドル</td>
</tr>
<tr>
<td>Steve Chesney</td>
<td>Redburn Atlantic</td>
<td>発表</td>
<td>Buy</td>
<td>545.00ドル</td>
<td>&#8211;</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>ウェルズ・ファーゴ</td>
<td>引き上げ</td>
<td>Overweight</td>
<td>555.00ドル</td>
<td>540.00ドル</td>
</tr>
<tr>
<td>Jasper Hellweg</td>
<td>アーガス・リサーチ</td>
<td>引き上げ</td>
<td>Buy</td>
<td>550.00ドル</td>
<td>465.00ドル</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBCキャピタル</td>
<td>引き下げ</td>
<td>Sector Perform</td>
<td>421.00ドル</td>
<td>424.00ドル</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBCキャピタル</td>
<td>維持</td>
<td>Sector Perform</td>
<td>424.00ドル</td>
<td>424.00ドル</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMOキャピタル</td>
<td>引き上げ</td>
<td>Outperform</td>
<td>500.00ドル</td>
<td>480.00ドル</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>維持</td>
<td>Buy</td>
<td>462.00ドル</td>
<td>462.00ドル</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBCキャピタル</td>
<td>引き上げ</td>
<td>Sector Perform</td>
<td>424.00ドル</td>
<td>417.00ドル</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>引き上げ</td>
<td>Overweight</td>
<td>456.00ドル</td>
<td>450.00ドル</td>
</tr>
</tbody>
</table>
<h3>重要な洞察</h3>
<ul>
<li>行動：動的な市況と企業の業績に対応して、アナリストたちは自身の推奨内容を更新する。彼らが自分の見解を「維持」するか、「引き上げ」や「引き下げ」をするか、それはVertex Pharmaceuticalsに関連する最近の動向に対する反応を示すものである。この洞察が、アナリストたちの視点を使って、現在の同社の状況を把握する手助けとなる。</li>
<li>評価：アナリストたちが株式のパフォーマンスについて「アウトパフォーム」から「アンダーパフォーム」までの見解を示すことで、投資家に対して質的なインサイトが提供される。これらの格付けは、Vertex Pharmaceuticalsの株価が全体市場に対してどのようなパフォーマンスを見せるかという点に対するアナリストの見解を伝える。</li>
<li>株価ターゲット：アナリストたちは株価ターゲットについての見解を提供し、Vertex Pharmaceuticalsの株価が先行きどのような値になるかの予測を提示する。この比較を通じて、アナリストたちの期待が時間の経過とともにどのように変化しているかが明らかになる。</li>
</ul>
これらのアナリストの評価が示すものに加えて、他の財務指標を探求することで、Vertex Pharmaceuticalsの市場動向に関する包括的な理解が得られる。弊社のRatings Tableを活用して、最新の情報をキャッチアップし、データ主導の意思決定を行ってほしい。
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Vertex Pharmaceuticalsのアナリスト・レーティングについて最新情報を入手しましょう。</a>
<h2>Vertex Pharmaceuticalsに関する全ての情報</h2>
Vertex Pharmaceuticalsは、重篤な疾患の治療に向けて小分子医薬品を発見・開発するグローバルなバイオテクノロジー企業である。同社の主要製品は、Kalydeco、Orkambi、Symdeko、およびTrikafta/Kaftrioであり、これらは嚢胞性線維症の治療に使用されており、Vertexの治療法は世界中で標準治療として使用されている。Vertexは、β型地中海貧血および鎌状赤血球症向けの遺伝子編集療法であるCrispr-Cas9を使用した製品として、Casgevを通じて自社製品ポートフォリオを多様化させている。さらに、Vertexは、非オピオイド治療法を使用して急性および慢性疼痛を標的とする小分子阻害剤、および、APOL1 によって引き起こされる腎臓疾患を標的とする小分子阻害剤を評価している。 Vertexは、1型糖尿病に対する潜在的な機能的治癒を提供する細胞療法についても調査を行っている。
<h3>Vertex Pharmaceuticalsの経済への影響：分析</h3>
時価総額の分析：同社の売上高は産業平均を上回っており、その存在感は大きい。これは同社が大規模であり、市場での認知度が高いことを反映している。
売上高のポジティブな推移：3か月間の間にVertex Pharmaceuticalsの財務状況を見ると、そのポジティブな推移が読み取れる。同社は2024年3月31日現在で、売上高（総収益の上昇）で 13.3% の成長率を達成し、その結果、売上高は大幅に増加した。同社はヘルスケアセクターにおける競合他社と比較して、この分野の平均成長率よりも低い成長率の結果となった。
純利益率：同社の純利益率は業界平均を上回っており、その競争力の高さが浮き彫りになっている。同社の純利益率は40.87%という素晴らしい数字を記録し、これは同社が利益を上手く出し、効果的な原価管理をしていることを示している。
株主資本利益率（ROE）：Vertex PharmaceuticalsのROEは、業界標準を上回っており、同社の優れた財務パフォーマンスを示している。同社のROEは6.09%という素晴らしい数字を記録しており、同社は株主資本を効果的に活用している。
総資産利益率（ROA）：Vertex PharmaceuticalsのROAも業界平均を上回っている。同社のROAは4.71%という素晴らしい数字を記録しており、同社は資産を効果的に活用し、強い財務パフォーマンスを示している。
債務管理：同社は、債務割合が業界標準を下回るバランスの取れた債務アプローチを維持しており、その債務比率は0.04となっている。
<h2>アナリスト評価の重要性について</h2>
アナリストは銀行や金融機関で働いており、通常は株式や特定のセクターについてレポートを専門としている。アナリストは企業の会議電話や会議に参加し、企業の財務諸表を研究し、関係者とコミュニケーションを取りながら、株式の「アナリスト・レーティング」を発表する。アナリストは通常、各株式について四半期に一度だけレーティングを行う。
アナリストは、それぞれの株式について、成長率の予測や収益、売上高の予測などの予測を補足することがあるため、投資家はこれらの情報を利用して、投資先についてより包括的な見方を行うことができる。ただし、アナリストは人間であるため、予測に影響を与える主観的な視点を持っている可能性があるため、これに留意する必要がある。
本記事はBenzingaの

Comments

Vertex Pharmaceuticals

ニュース

最新ニュース Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報

水曜日, 7 31, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル